Nonpathogenic Escherichia coli strain Nissle 1917 inhibits signal transduction in intestinal epithelial cells

被引:52
作者
Kamada, Nobuhiko [1 ]
Maeda, Kenichi [2 ]
Inoue, Nagamu [1 ]
Hisamatsu, Tadakazu [1 ]
Okamoto, Susumu [1 ]
Hong, Kyong Su [2 ]
Yamada, Takaya [3 ]
Watanabe, Noriaki [4 ]
Tsuchimoto, Kanji [4 ]
Ogata, Haruhiko [1 ]
Hibi, Toshifumi [1 ]
机构
[1] Keio Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol,Shinjuku Ku, Tokyo 1608582, Japan
[2] JCR Pharmaceut Co Ltd, Res Ctr, Div Res, Kobe, Hyogo, Japan
[3] Shimane Univ, Ctr Integrated Res Sci, Dept Expt Anim, Izumo, Shimane, Japan
[4] Kitasato Inst Hosp, Dept Internal Med, Tokyo, Japan
关键词
D O I
10.1128/IAI.01193-07
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Although the probiotic Escherichia coli strain Nissle 1917 has been used for the treatment of inflammatory bowel diseases, the precise mechanisms of action of this strain remain unclear. In the present study, we estimated the anti-inflammatory effect of E. coli Nissle 1917 on inflammatory responses in vitro to determine the suppressive mechanism of Nissle 1917 on the inflammatory process. To determine the effect of E. coli Nissle 1917, the human colonic epithelial cell line HCT15 was incubated with or without E. coli Nissle 1917 or another nonpathogenic E. coli strain, K-12, and then tumor necrosis factor alpha (TNF-alpha)-induced interleukin-8 (IL-8) production from HCT15 cells was assessed. Enzyme-linked immunosorbent assays and real-time quantitative PCR showed that Nissle 1917 treatment suppressed TNF-alpha-induced IL-8 transcription and production. In addition, results from luciferase assays indicated that Nissle 1917 inhibited IL-8 promoter activity. On the other hand, these anti-inflammatory effects were not seen with E. coli K-12. In addition, heat-killed Nissle 1917 or its genomic DNA did not have this anti-inflammatory effect. Surprisingly, Nissle 1917 did not affect IL-8 transactivation pathways, such as NF-kappa B activation, nuclear translocation, and DNA binding, or even activation of other transcriptional factors. Furthermore, it also became evident that Nissle 1917 induced the anti-inflammatory effect without contact to epithelial cells. In conclusion, these data indicate that the nonpathogenic E. coli strain Nissle 1917 expresses a direct anti-inflammatory activity on human epithelial cells via a secreted factor which suppresses TNF-alpha-induced IL-8 transactivation through mechanisms different from NF-kappa B inhibition.
引用
收藏
页码:214 / 220
页数:7
相关论文
共 31 条
[21]   Paneth cells, defensins, and the commensal microbiota: A hypothesis on intimate interplay at the intestinal mucosa [J].
Salzman, Nita H. ;
Underwood, Mark A. ;
Bevins, Charles L. .
SEMINARS IN IMMUNOLOGY, 2007, 19 (02) :70-83
[22]   Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: Antibiotics, probiotics, and prebiotics [J].
Sartor, RB .
GASTROENTEROLOGY, 2004, 126 (06) :1620-1633
[23]   Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis [J].
Sartor, RB .
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2006, 3 (07) :390-407
[24]   Induction of human β-defensin 2 by the probiotic Escherichia coli nissle 1917 is mediated throuah flagellin [J].
Schlee, Miriam ;
Wehkamp, Jan ;
Altenhoefer, Artur ;
Oelschlaeger, Tobias A. ;
Stange, Eduard F. ;
Fellermann, Klaus .
INFECTION AND IMMUNITY, 2007, 75 (05) :2399-2407
[25]   Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis [J].
Schultz, M ;
Strauch, UG ;
Linde, HJ ;
Watzl, S ;
Obermeier, F ;
Göttl, C ;
Dunger, N ;
Grunwald, N ;
Schölmerich, J ;
Rath, HC .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2004, 11 (02) :372-378
[26]  
Spöttl T, 2001, J LEUKOCYTE BIOL, V70, P241
[27]   Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling [J].
Sturm, A ;
Rilling, K ;
Baumgart, DC ;
Gargas, K ;
Abou-Ghazalé, T ;
Raupach, B ;
Eckert, J ;
Schumann, RR ;
Enders, C ;
Sonnenborn, U ;
Wiedenmann, B ;
Dignass, AU .
INFECTION AND IMMUNITY, 2005, 73 (03) :1452-1465
[28]   DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF METRONIDAZOLE IN CROHNS-DISEASE [J].
SUTHERLAND, L ;
SINGLETON, J ;
SESSIONS, J ;
HANAUER, S ;
KRAWITT, E ;
RANKIN, G ;
SUMMERS, R ;
MEKHJIAN, H ;
GREENBERGER, N ;
KELLY, M ;
LEVINE, J ;
THOMSON, A ;
ALPERT, E ;
PROKIPCHUK, E .
GUT, 1991, 32 (09) :1071-1075
[29]  
TAUROG JD, 1993, J IMMUNOL, V150, P4168
[30]   NF-κB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917:: A novel effect of a probiotic bacterium [J].
Wehkamp, J ;
Harder, J ;
Wehkamp, K ;
Wehkamp-von Meissner, B ;
Schlee, M ;
Enders, C ;
Sonnenborn, U ;
Nuding, S ;
Bengmark, S ;
Fellermann, K ;
Schröder, JM ;
Stange, EF .
INFECTION AND IMMUNITY, 2004, 72 (10) :5750-5758